LABCORP HOLDINGS INC.
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Insider Adoption or Termination of Trading Arrangements:
During the quarter ended March 31, 2026, none of the Company’s directors or officers informed it of the adoption, modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as described in the table below:
| Name and Title · Date Adopted · Character of Trading Agreement · Aggregate Number of Shares of Common Stock to be (Sold) Purchased Pursuant to Trading Agreement · Expiration Date | ||||||
|---|---|---|---|---|---|---|
| Kathryn W. Kyle | March 9, 2026 | Rule 10b5-1 Trading Arrangement | (1,633) | (1)(2) | April 9, 2027 | (3) |
| Executive Vice President, Chief Legal Officer and Corporate Secretary | ||||||
| Bryan T. Vaughn | March 8, 2026 | Rule 10b5-1 Trading Arrangement | (2,813) | (1) | May 7, 2027 | (3) |
| Executive Vice President, Diagnostics | ||||||
(1)The figure presented represents the shares to be sold on the vesting of equity awards and may vary subject to the achievement of certain performance conditions and/or shares to be withheld for tax purposes.
(2)Ms. Kyle’s plan provides for the sale of up to 195 shares of Common Stock previously acquired from an equity award vesting event.
(3)This trading arrangement permits transactions through the completion of all sales on the respective order entry date.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.